<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Diabetetic Nephropathy • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Diabetetic Nephropathy • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/diabetetic nephropathy/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/diabetetic nephropathy/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="diabetetic-nephropathy" tabindex="-1">diabetetic nephropathy</h1>
<ul>
<li>related: <a href="/wiki/notes/Nephrology/">Nephrology</a></li>
<li>tags: #nephrology</li>
</ul>
<hr>
<p>The cornerstone of treatment of diabetic nephropathy involves <mark>glycemic control and blood pressure control</mark>. Blockade of the renin-angiotensin system with an <mark>ACE inhibitor or angiotensin receptor blocker (ARB) is recommended, typically to the maximal tolerated dose</mark>, because these agents both reduce blood pressure and levels of proteinuria, which, along with glycemic control, are the most important modifiable risk factors for progression of diabetic nephropathy to ESKD. Combined use of any two of the three renin-angiotensin system drug classes (ACE inhibitor, ARB, and direct renin inhibitor) is not recommended given the results of several clinical trials that revealed more adverse events with these combinations (hyperkalemia, hypotension, AKI), without additional cardiovascular or renal benefits. <mark>Combining ACE inhibitors or ARBs with mineralocorticoid receptors</mark> (spironolactone or eplerenone) has been shown in small studies to be a safe and effective antiproteinuric strategy in diabetic nephropathy, but the <mark>risk for hyperkalemia</mark> should be considered. For patients with type 2 diabetes and CKD, the American Diabetes Association recommends that physicians consider use of a <mark>sodium–glucose cotransporter 2 inhibitor</mark> when the estimated glomerular filtration rate <mark>is &gt;30 mL/min/1.73 m2 with a urine albumin-creatinine ratio &gt;30 mg/g</mark>. The recommendation is <mark>more strongly advised in patients with a higher-grade albuminuria</mark> (urine albumin-creatinine ratio &gt;300 mg/g), in which the sodium–glucose cotransporter 2 inhibitor will reduce progression of kidney disease and/or cardiovascular events. In patients with CKD who have additional cardiovascular risk factors, a <mark>glucagon-like peptide 1 receptor agonist</mark> will also reduce the risk for CKD progression, cardiovascular events, or both.</p>
<p>The 2017 high blood pressure guideline from the American College of Cardiology (ACC), the American Heart Association (AHA), and nine other organizations recommends a <mark>blood pressure target of &lt;130/80 mm Hg</mark> for patients with hypertension and diabetes mellitus and/or CKD. The American Diabetes Association recommends that most patients with diabetes and hypertension should be treated to a systolic blood pressure goal of &lt;140 mm Hg and a diastolic blood pressure goal of &lt;90 mm Hg; lower systolic and diastolic blood pressure targets, such as 130/80 mm Hg, may be appropriate for individuals at high risk of cardiovascular disease, if they can be achieved without undue treatment burden.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Nephrology/" class="peer">Nephrology</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="nephrology" tabindex="-1">Nephrology</h1>
<hr>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2 id="to-learns" tabindex="-1">To learns</h2>
<ul>
<li>ANCA vasculitis</li>
<li>[ ] stones: citrate and calcium physiology</li>
</ul>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<p>Chapter 01Clinical Evaluation of Kidney Function
Chapter 02Fluids and Electrolytes
Chapter 03Acid-Base Disorders
Chapter 04Hypertension
Chapter 05Chronic Tubulointerstitial Nephritis
Chapter 06Glomerular Diseases</p>
<ul>
<li><a href="/wiki/notes/Kidney%20Manifestations%20of%20Deposition%20Diseases/">Kidney Manifestations of Deposition Diseases</a>
Chapter 08Genetic Disorders and Kidney Disease
Chapter 09Acut</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
